



ASX / Media Release

21st January 2016

Dr Chris Roberts appointed Non-Executive Director

SYDNEY, 21st January, 2016: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce the appointment today of Dr Chris Roberts as an Independent Non-Executive Director of the Company, with immediate effect.

Dr Roberts is a highly experienced director and senior executive with 40 years' experience in the medical innovation space. During this time he has served on the boards of a number of ASX listed companies as well as research institutions and government entities.

Dr Roberts has forged a long and successful career in the medical device sector. He was Chief Executive Officer/President of Cochlear Limited (ASX: COH) from February 2004 to August 2015. Cochlear is the global market leader in implantable devices, such as cochlear implants, for the hearing impaired. Dr Roberts was primarily responsible for the significant increase in Cochlear Limited's sales from \$348m in 2005 to \$926m in 2015.

Dr Roberts was also previously Chairman of Sirtex Medical Ltd (ASX: SRX), from March 2000 to December 2002, and was Executive Vice-President of global sleep disorder treatment company ResMed Inc (NYSE: RMD, ASX: RMD) from 1992 to 2004. He is currently a Non-executive Director of ResMed Inc.

Dr Roberts also sits on the boards of a number of other entities and groups including; Jobs NSW, NSW Innovation and Productivity Council, University of Technology Sydney Vice-Chancellor's Industry Advisory Board, the University of New South Wales Faculty of Medicine Advisory Council, Monash University Industry Council of Advisors and the Health Innovation Advisory Committee, which is a principal committee of the National Health and Medical Research Council.

He is a member of the Board of Governors of the Centenary Institute of Cancer Medicine and Cell Biology, and is an Honorary Fellow of the Australian Institute of Business and Economics at the University of Queensland.

Dr Roberts holds a BE (Honours) in Chemical Engineering (UNSW), an MBA (Macq) and a PhD (UNSW) and was awarded Honorary Doctor of Science degrees from Macquarie University and the University of NSW. He is a Fellow of the Academy of Technological Sciences and Engineering (FTSE), Fellow of the Australian Institute of Company Directors (FAICD) and Honorary Fellow of The Institution of Engineers Australia (FIEAust).

OncoSil Medical CEO Mr Daniel Kenny said: *"We are delighted to welcome someone of the calibre of Dr Roberts to our Board of Directors. Dr Roberts' outstanding track record of achievement across multiple disciplines in the commercialisation of medical innovation will be a valuable addition to the Board, as the Company continues to advance the commercialisation of OncoSil™ as a medical radiation treatment for pancreatic cancer and other solid tumours."*

Commenting on his appointment, Dr Roberts said: *"I am delighted to join the OncoSil Medical team at this time, as the Company moves to commercialise its OncoSil™ technology. The opportunity to participate in the commercialisation of this innovative medical technology that has the potential to substantially improve the lives of people with cancer, particularly pancreatic cancer is very exciting."*

Subject to and upon receiving shareholder approval, Dr Roberts will receive, under the Company's Employee Incentive Scheme, a Company loan funded share package for 10 million fully paid ordinary shares at an issue price per share equal to their market price at the time of their issue. These shares will vest in 4 equal tranches over the next 5 years (subject to the Company reaching certain aggregate product sales results for each tranche and Dr Roberts agreeing to commence the role as Chairman of the Company within the next 12 months). The loan will be a limited recourse loan to Dr Roberts for a period of 5 years. A Notice of Meeting seeking shareholder approval for the issue of loan funded shares will be announced and distributed to shareholders as soon as practical.

ENDS

Contact:

Mr Daniel Kenny
Chief Executive Officer and Managing Director

E: daniel.kenny@oncosil.com.au

T: +61 2 9223 3344

James Moses
Mandate Corporate

E: james@mandatecorporate.com.au

M: +61 420 991 574

T: +61 2 8211 0612

About OncoSil Medical Ltd

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian Lifesciences company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and CE Mark approval for pancreatic cancer is the core focus of OncoSil Medical.

Pancreatic Cancer

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma liver cancer

Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. It's very poor prognosis makes HCC the third leading cause of cancer related mortality responsible for approximately 600,000 deaths annually. Hepatocellular carcinoma can be cured by surgery or transplantation. The vast majority of patients with HCC have disease which is too advanced for surgical intervention and as a consequence survival ranges from a few months to two or more years depending on the liver function at diagnosis and the extent of tumour invasion. The value of the hepatocellular cancer (HCC) market is expected to triple in size to \$1.4b by 2019.

References

- Global Industry Analysts 2010
- BIOSDP-201. A single dose, single centre open label Phase I/II Safety Study in Hepatocarcinoma
- Venook et al. The incidence of Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist; 15 Supplement 5-13
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/pancreatic-cancer-statistics>
- <http://www.datamonitorhealthcare.com/hepatocellular-cancer-market-to-treble-in-size-by-2019>
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/liver-cancer-statistics>